NCT05055791View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

312

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

June 20, 2026

Study Completion Date

September 20, 2026

Conditions

Acute Myeloid LeukemiaLymphomaMultiple Myeloma

Interventions

DRUG

SYHX1903

SYHX1903 tablets, orally, qd

All Listed Sponsors

lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY